Mealey's (March 26, 2021, 12:45 PM EDT) -- SAN DIEGO — Sixteen days after a California federal judge granted summary judgment in the incretin mimetic multidistrict litigation on the basis of preemption, experts and causation, four diabetes drug manufacturers...
Diabetes Drug Makers Seek $686,002 In Fees, Costs After Preemption Win In MDL
To view the full article, register now.
Try for FREE for fourteen days
Already a subscriber? Click here to login